摘要
目的 观察心脏X综合征病人血循环中高敏C反应蛋白的变化以及阿托伐他丁的可能影响。方法 选取 2 5例心脏X综合征病人和 10例健康人。⑴比较心脏X综合征病人和健康人血清hs -CRP水平 ;⑵比较胸痛频率每周≥ 5次 (n =14 )和 <5次 (n =11)两组心脏X综合征病人血清hs -CRP的水平 ;⑶比较胸痛持续时间≥ 15min(n =13 )和 <15min(n =12 )两组血清hs -CRP的水平 ;⑷ 2 5例病人分为对照组 (n =12 ,予以消心痛 10mgTid和地尔硫卓 3 0mgTid)和治疗组 (n =13 ,在前者基础上加阿托伐他丁 2 0mgQD) ,持续 12周 ,比较两组胸痛症状和hs -CRP的变化。结果 ⑴心脏X综合征病人血清hs -CRP显著高于健康人[( 3 7± 3 2mg/Lvs 0 9± 0 5mg/L ,P <0 0 1) ] ;⑵胸痛频率每周≥ 5次组血清hs -CRP高于 <5次组 [( 3 8± 2 4mg/Lvs 2 6± 2 6mg/L ,P <0 0 5 ) ] ;⑶胸痛持续时间≥ 15min组血清hs -CRP高于 <15min组 [( 3 9± 3 0mg/Lvs 2 7± 1 7mg/L ,P <0 0 1) ] ;⑷阿托伐他丁治疗组血清hs -CRP下降较对照组显著 [( 1 3± 1 6mg/Lvs 2 8± 3 1mg/L ,P <0 0 1) ] ,胸痛症状缓解更明显。结论 ⑴hs -CRP可能与心脏X综合征的发病相关 ;⑵阿托伐他丁有助于降低心脏X综合征病人的hs
Objective To explore the level changes of serum hypersensitive C-reactive protein (hs-CRP) in patients with cardiac syndrome X (CSX) and the effect of atorvastatin on hs-CRP level. Methods 25 patients with CSX and 10 matched healthy subjects were enrolled in this study, and the serum hs-CRP levels were compared between the patients and healthy subjects. The patients were randomly devidid into routine therapy group (n=12), which received diltiazem 30mg t.i.d and isorbide dinitrate 10mg t.i.d, and atovastatin thrapy group (n=13), which received the same dosage of diltiazem and isobide dinitrate, and atovastatin 20mg/d additionally. The course of treatment was 12 weeks. At the beginning and the end of study, standardized angina questionnaires and exercise stress test were performed in all patients, and their serum hs-CRP levels were measured. Results ⑴The serum hs-CRP levels of patients with CSX were significantly hagher than those of healthy subjects(3 7±3 2mg/L vs 0 9±0 5mg/L, P<0 01); ⑵The serum hs-CRP levels of patients with frequent chest pain (≥5 episodes/week) were higher than those of patients with less frequent chest pain(<5 episodes/week) (3 8±2 4mg/L vs 2 6±2 6mg/L, P<0 05); ⑶The serum hs-CRP levels of patients with long duration chest pain (≥15 min/episode) were higher than those of patients with short duration chest pain(<15 min/episode) (3 9±3 0mg/L vs 2 7±1 7mg/L, P<0 01); ⑷The serum hs-CRP levels of patients in atovastatin thrapy group were significantly lower than those of patients in routine therapy group (1 3±1 6mg/L vs 2 8±3 1mg/L, P<0 01), and symptoms of chest pain in atorvastatin therapy group were improved more obviously compared with routine therapy group. Conclussions The hs-CRP might correlate with the pathogenesis of CSX. Atovastatin might be useful to decrease the serum hs-CRP level and to alleviate the symptom of chest pain in the patients with CSX.
出处
《中国医师杂志》
CAS
2004年第9期1212-1213,1268,共3页
Journal of Chinese Physician
